Dupixent

Regeneration of monoclonal antibody drug Dupixent yuan / Sanofi joint development (dupilumab) is approved by FDA at the end of March 2017. The action mechanism of this drug is to inhibit the immune response regulated by cytokine IL-4R/IL-13R. Dupixent will be the first systematic treatment for the treatment of eczema or moderate to severe allergic dermatitis.

Ocrevus

Ocrevus (ocrelizumab), developed by Roche, is expected to be approved in mid 2017. The medication of this drug includes relapsed remission multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). The biggest feature of Ocrevus is that it is a 6 - month infusion and only 2 times a year. It is expected to significantly improve the compliance of patients with multiple sclerosis.

Praluent/Repatha

Sanofi Praluent and Amgen's Repatha approved in the United States in 2015. Praluent (alirocumab) and Repatha (evolocumab) is a PCSK9 inhibitor, PCSK9 inhibitor is a kind of monoclonal antibody drug target is a protein convertase subtilisin / Kexin type 9 (PCSK9) protein, the protein can reduce the hepatic clearance of low-density lipoprotein cholesterol from the blood (LDL-C) and the ability of LDL-C cardiovascular disease is regarded as the main risk factor (CVD). Clinical studies showed that the level of LDL in patients taking PCSK9 inhibitor drugs was reduced by more than 55%-60%. The effect is remarkable.

Spinraza

Spinraza (nusinersen) is Biogen’ the first drug for the treatment of spinal muscular atrophy, developed by s, is now listed in the United States. The drug is an antisense oligonucleotide drug. Through intrathecal administration, Spinraza sends the active ingredients directly to the cerebrospinal fluid (CSF) around the spinal cord, and spinal cord is a spinal muscular atrophy. Due to the deficiency of SMN protein level, motor neuron degeneration and degeneration occur. Clinical data showed that 40% of the patients with Spinraza were significantly improved after the treatment.

Durvalumab

The clinical trial results of the combination of AstraZeneca PD-L1 monoclonal antibody durvalumab and CTLA-4 monoclonal antibody tremelimumab in non-small cell lung cancer (NSCLC) first line treatment will be released in mid 2017. Meanwhile, AstraZeneca is launching a widely clinical project on durvalumab, including hematologic malignancies, pancreatic cancer, gastric cancer, head and neck cancer, bladder cancer and so on.

Keytruda

The results of a phase III study of first-line treatment of NSCLC will be announced at the end of 2017 combined with Merck's first Keytruda PD-1/PD-L1 monoclonal antibody with chemotherapy drugs. Keytruda is the most popular drug choice in the field of lung cancer immunotherapy.

KTE-C19 / CTL019

Kite and Novartis will complete the listing application of KTE-C19 and CTL019 in 2017 early stage for relapsed or refractory B cells, non Hodgkin lymphoma, children and adolescents with relapsed or refractory B acute lymphoblastic lymphoma. The latest clinical trial data showed that in patients receiving CTL019 treatment, the total survival rate was 89% within 6 months, and 60% of the patients did not have a relapse. Another clinical trial showed that KTE-C19 had a significant effect in the treatment of non Hodgkin's lymphoma which did not respond to traditional therapy. The compound objective remission rate was 44%, and the complete remission rate was 39%, which is significantly better than other traditional therapies.

Nuplazid

Acadia's Nuplazid was approved by FDA in April 29, 2016. It is the first FDA approved drug targeting 5-HT2A receptor. It is also the first FDA approved treatment for Parkinson's disease psychosis. It is a significant milestone in the clinical treatment of Parkinson's disease psychosis. The subsequent phase II study revealed that Nuplazid has the potential to treat Alzheimer's disease.

Perjeta

Roche's Perjeta and Herceptin adjuvant therapy for HER2 positive breast cancer showed significant anti-tumor activity and improved the immunity of Herceptin to generic drugs. Herceptin+Perjeta+ chemotherapy &rdquo has been approved by more than 75 countries worldwide for the neoadjuvant therapy of HER2+ breast cancer, and has become the standard therapy for HER2+ breast cancer patients.

.

At present, all the drugs have not yet been listed on the mainland of China, and patients who want to obtain such drugs can only be purchased from the United States or Hongkong through overseas routes. Hangzhou Health Management Consulting Co., Ltd. provides an overseas medical direct train to help patients travel to cost-effective medical institutions.

Hangzhou medical marketing Health Management Co., Ltd. provides one-stop international medical consultation service, allowing more patients to enjoy the latest international medical achievements. Welcome to call 400-0825-008 hotline.